Correlation between Psoriasis Area Severity Index and Dermatology Life Quality Index in psoriasis
Keywords:
Psoriasis, PASI Score, DLQIAbstract
Background: Validated dermatology-specific quality of life tools are used globally to quantify the degree to which a skin disorder affects a patient's quality of life. Methods: A cross-sectional study of patients with psoriasis was conducted. Patients were evaluated for psoriasis severity using the Psoriasis Area and Severity Index (PASI) and its correlation with Dermatology Life Quality Index (DLQI) was assessed. Results: 60 patients were enrolled in this study. PASI and DLQI were found to be significantly correlated (r= 0.266 p = 0.044) but the degree of correlation was much lower than that found in European studies. However, post-stratification data analysis did not show a significant relationship between PASI and DLQI except in male patients (r=0.415, p = 0.006) and in patients with disease duration between 1-6 years (r = 0.579, p=0.002). Conclusion: The correlation between PASI and DLQI was weaker than what has previously been reported. Further validation of culturally-sensitive dermatologic quality of life instruments is needed to capture the true impact of skin disease in these patients. Currently, DLQI fails to efficiently recognize some clinically important endpoints and may not be much relevant for routine clinical practice in our society. Keywords: Psoriasis, PASI, DLQIReferences
Damiani G, Bragazzi NL, Karimkhani Aksut C, Wu D, Alicandro G, McGonagle D, Guo C, Dellavalle R, Grada A, Wong P, La Vecchia C. The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study. Front Med. 2021;16(8):743180.
Ograczyk A, Miniszewska J, Kępska A, Zalewska-Janowska A. Itch, disease coping strategies and quality of life in psoriasis patients. Postepy Dermatol Alergol. 2014;31(5):299.
Al-Mutairi N, Eassa BE, Nair V. Measurement of vitamin D and cathelicidin (LL-37) levels in patients of psoriasis with co-morbidities. Indian J Dermatol Venereol Leprol. 2013;79(4):492.
Schons KRR, Beber AAC, Beck MdO, Monticielo OA. Nail involvement in adult patients with plaque-type psoriasis: prevalence and clinical features. An Bras Dermatol. 2015;90(3):314-9.
Hawro T, Zalewska A, Hawro M, Kaszuba A, Królikowska M, Maurer M. Impact of psoriasis severity on family income and quality of life. J Eur Acad Dermatol Venereol. 2015;29(3):438-43.
Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Sump Proc. 2004;9(2):169-180.
Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28(3):333-7.
Nayak PB, Girisha BS, Noronha TM. Correlation between disease severity, family income, and quality of life in psoriasis: A study from South India. Indian Dermatol Online J. 2018;9(3):165.
Soltandehghan K, Najafi-Ghezeljeh T. Relationship Between Quality of Life and Disease Severity in Patients with Psoriasis. NPT. 2017;4(3):143-53.
Khawaja, A.R., Bokhari, S.M.A., Rasheed, T., Shahzad, A., Hanif, M., Qadeer, F. and Jafferany, M. Disease severity, quality of life, and psychiatric morbidity in patients with psoriasis with reference to sociodemographic, lifestyle, and clinical variables: a prospective, cross-sectional study from Lahore, Pakistan. Prim Care Companion CNS Disord. 2015;17(3):26260.
Finlay AY, Khan G. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-6.
Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159(5):997-103.
